61 results on '"M. Meshref"'
Search Results
2. Coupling ATR-FTIR Spectroscopy and Chemometric Analysis for Rapid and Non-Destructive Ink Discrimination of Forensic Documents
- Author
-
Ahmed A. Gawad, Tarek M. Salama, M. Meshref, Gehad G. Mohamed, and Abdallah F. Zedan
- Published
- 2022
- Full Text
- View/download PDF
3. Tectonic framework
- Author
-
Wafik M. Meshref
- Published
- 2017
- Full Text
- View/download PDF
4. Barriers and Challenges to Global Clinical Cancer Research
- Author
-
Tanja Cufer, Lucía Delgado, Nise Hitomi Yamaguchi, Eduardo Cazap, Natasha B. Leighl, M. M. Meshref, Aleksander Sadikov, Eliezer Robinson, Doug Pyle, Bostjan Seruga, Raghunadharao Digumarti, and Hironobu Minami
- Subjects
Clinical Oncology ,Global Health and Cancer ,Internet ,Cancer Research ,medicine.medical_specialty ,Biomedical Research ,Data collection ,business.industry ,Data Collection ,Alternative medicine ,Global Health ,Medical Oncology ,Clinical research ,Oncology ,medicine ,Global health ,Cancer research ,Humans ,business - Abstract
Background. There are concerns about growing barriers to cancer research. We explored the characteristics of and barriers to global clinical cancer research. Methods. The American Society of Clinical Oncology International Affairs Committee invited 300 selected oncologists with research experience from 25 countries to complete a Web-based survey. Fisher's exact test was used to compare answers between participants from high-income countries (HICs) and low- and middle-income countries (LMICs). Barriers to clinical cancer research were ranked from 1 (most important) to 8 (least important). Mann-Whitney's nonparametric test was used to compare the ranks describing the importance of investigated obstacles. Results. Eighty oncologists responded, 41 from HICs and 39 from LMICs. Most responders were medical oncologists (62%) at academic hospitals (90%). Researchers from HICs were more involved with academic and industry-driven research than were researchers from LMICs. Significantly higher proportions of those who considered their ability to conduct academic research and industry-driven research over the past 5 years more difficult were from HICs (73% vs. 27% and 70% vs. 30%, respectively). Concerning academic clinical cancer research, a lack of funding was ranked the most important (score: 3.16) barrier, without significant differences observed between HICs and LMICs. Lack of time or competing priorities and procedures from competent authorities were the second most important barriers to conducting academic clinical research in HICs and LMICs, respectively. Conclusion. Lack of funding, lack of time and competing priorities, and procedures from competent authorities might be the main global barriers to academic clinical cancer research.
- Published
- 2013
- Full Text
- View/download PDF
5. A phase 2 study of the combination of gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines with/without taxanes
- Author
-
Ahmed Al Khodary, Mohsen Barsoum, Omar Mansour, M. M. Meshref, Iman Abdel Halim, Thoraya Abdel Hamid, Heba M El Zawahry, Emad Hamada, Saiid El Nowieam, Ahmed Abdel Wareth, Youssri Gouda, Rabbab Gaafar, Mohamed Abdullah, Fouad M Abou Taleb, Samir Shehata, and Hanna Kohail
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Anthracycline ,Phases of clinical research ,Breast Neoplasms ,Kaplan-Meier Estimate ,Neutropenia ,Deoxycytidine ,lcsh:RC254-282 ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Anthracyclines ,Neoplasm Metastasis ,Adverse effect ,Aged ,Salvage Therapy ,Taxane ,business.industry ,lcsh:RC633-647.5 ,General Medicine ,Hematology ,lcsh:Diseases of the blood and blood-forming organs ,Middle Aged ,medicine.disease ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Gemcitabine ,Metastatic breast cancer ,Chemotherapy regimen ,Female ,Cisplatin ,Neoplasm Recurrence, Local ,business ,medicine.drug - Abstract
BACKGROUND AND OBJECTIVES Many patients with relapsed metastatic breast cancer are pre-treated with taxanes and anthracyclines, which are usually given in the neoadjuvant/adjuvant setting or as first-line treatment for metastatic disease. The primary objective of this study was to determine the overall response rate for combination treatment with gemcitabine and cisplatin in patients with locally advanced or metastatic breast cancer who had relapsed after receiving one adjuvant/neoadjuvant or first-line metastatic chemotherapy regimen containing an anthracycline with/without a taxane. Secondary endpoints included duration of response, time to progression, one-year survival probability, and toxicity. DESIGN AND SETTING A single-arm, open-label, phase 2 study conducted at 17 investigative sites in Egypt. PATIENTS AND METHODS Treatment consisted of gemcitabine (1250 mg/m 2 ) on Days 1 and 8 and cisplatin (70 mg/m 2 ) on Day 1 of each 21-day cycle. Treatment continued until disease progression or a maximum of 6 cycles. RESULTS Of 144 patients all were evaluable for safety and 132 patients were evaluable for efficacy. The overall response rate was 33.3% and 45.5% of the patients with stable disease as their best response. The median time to progression was 5.1 months and the one-year survival probability was 73%. The most common grade 3/4 adverse events were nausea/vomiting (20.1%), neutropenia (19.4%), anemia (13.9%), asthenia (11.1%), diarrhea (9.7%), stomatitis (7.6%), leucopenia (7.6%), and thrombocytopenia (6.2%). Twelve (8.3%) patients had serious adverse events. CONCLUSIONS The results of this study indicate that gemcitabine and cisplatin were active and generally well tolerated in pretreated patients with locally advanced or metastatic breast cancer.
- Published
- 2012
6. GRAIN YIELD AND STABILITY OF THE NEW DURUM WHEAT CULTIVAR BANI SUEF 6
- Author
-
A. Hamada, M. A. Gouda, S. Kh. Mahmoud, H. Ashoush, E. El-Sayed, A. T. Mostafa, A. Abo-Warda, A. Tammam, A. Swelam, W. Abdel-Samad, M. Meshref, Najwa Abdel-Fattah, A. El-Hag, A. Gomaa, Hayam S. Mahgoub, Enayat Ghanem, A. Menshawy, Wafaa M. El-Awady, M. A. Hassan, M. A. El-Maghraby, G. Sharawy, M. El-Monofy, S. Abdel-Dayem, S. Seleem, M. A. Khaled, H. El-Borham, F. Hefnawy, A. Ageez, N. Hanna, I. A. Amin, M. Tawfelies, E. A. Yossef, M. S. Mahmoud, M. S. Shrshar, M. Abo Shereef, Manal A. Hassan, M. A. Salem, A. Moussa, M. Zakaria, Hoda M. M. El-Gharbawy, S. El-Sawy, Sabah Abo El-Ela, Aza M. Abdel-Al, Magda A. Abdel-Rahman, T. Shehab El-Din, A. Khattab, A. Hagras, A. Morad, S. Abdel-Majeed, A. Abdel-Lattif, Sohair M. Hassan, R. Koumbor, M. Abdel-Aleem, Eman M. Sadek, M. Y. Mubark, Nadia A. Abdel-Nour, A. A. Mahmoud, H. Hendawy, A. K. Mostafa, M. A. Moustafa, S. Hammad, M. A. Moussa, S. R. Sabry, A. Gad-Allah, and R. A. Ramadan
- Subjects
chemistry.chemical_classification ,Horticulture ,biology ,chemistry ,Yield (wine) ,Grain yield ,Cultivar ,Stem rust ,biology.organism_classification ,Rust ,Gluten ,High yielding ,Clearance - Abstract
The new promising durum wheat cultivar Bani Suef 6 was newly released from Wheat Research Department, Field Crops Research Institute, ARC, Egypt. Bani Suef6 has been selected from CIMMYT materials grown at Sids Agricultural Research Station. Yield evaluation was performed through 31 experiments conducted at different levels of preliminary and advanced yield trials during the three successive growing seasons from 2004/2005 to 2006/2007. The results revealed that the new durum wheat cultivar Bani Suef6 has high yielding ability compared with commercial durum wheat cultivars. Moreover, stability analysis for grain yield showed that Bani Suef 6 has better stability parameters in the three main regions for durum wheat cultivated in Egypt, i.e., Middle Egypt, Upper Egypt and Out Valley. Also, the results of rust diseases reactions cleared that Bani Suef 6 has high resistance to leaf and stem rust diseases. Studies on yield components of Bani Suef 6 revealed that the new cultivar had significantly surpassed the check durum cultivars in number of spikes/m2, number of kernels/spike and higher 1000-kernel weight confirming the contribution of yield components in improving grain yield of the new durum cultivar Bani Suef 6. Studies on number of days to heading revealed that Bani Suef 6 recorded 98.7 days to heading which was earlier than some durum cultivars and almost equal to the average of all cultivars (99.1 days). Similarity, Bani Suef 6 was the earliest in physiological maturity (147.7 days) while other durum checks ranged from 149.0 to 150.8 with an average of 149.7 days. Bani Suef 6 recorded the lowest plant height (101.0 cm vs. 106.0 cm for the average of other cultivars). Physical and chemical analyses of durum wheat grains showed that the new cultivar Bani Suef 6 had a higher score over the average of the other four durum cultivars in hectoliter (83.1 vs. 82), Semolina (77.0 vs. 76.6%), protein (12.9 vs. 12.3%), wet gluten (29.6 vs. 28.4%) and dry gluten (10.8 vs. 10.0%).
- Published
- 2011
- Full Text
- View/download PDF
7. Smoking and Prognostic Factors in an Observational Setting in Patients with Advanced Non-Small Cell Lung Carcinoma
- Author
-
Kurt Krejcy, Zbigniew Kadziola, Younseup Kim, Salih Z Guclu, Chien-Te Li, Sedat Altug, M. M. Meshref, Shukui Qin, and Magdalena Marek
- Subjects
Oncology ,Pediatrics ,medicine.medical_specialty ,Performance status ,predictive modeling ,business.industry ,Proportional hazards model ,Hazard ratio ,prognostic factors ,NSCLC ,medicine.disease ,smoking ,Regimen ,Internal medicine ,medicine ,Carcinoma ,Observational study ,observational ,Stage (cooking) ,business ,Survival analysis ,Research Paper - Abstract
Background: This prospective observational study estimated the effect of prognostic factors, particularly continued smoking during therapy, on survival in advanced non-small cell lung cancer (NSCLC) patients receiving gemcitabine-platinum. Further, prognostic factors were used to build a survival model to improve prognosis prediction in naturalistic clinical settings. Methods: Eligibility criteria included: Stage IIIB/IV NSCLC, no prior chemotherapy, and Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. A Cox regression model was constructed and validated by randomizing patients into two datasets (Construction [C]:Validation [V]; 3:1 ratio). Country, disease stage, hypercalcemia, “N” factor, weight reduction, performance status, and superior vena cava obstruction were pre-defined variables forced into the model. Continued smoking was tested with adjustment for these variables. Results: One thousand two hundred and fourteen patients (C=891 and V=323) were enrolled. The final predictive model, established in the Construction dataset, identified four significant (p≤0.05) and independent predictors of survival, which were disease stage, performance status, gemcitabine-platinum regimen, and T-stage. Smoking during therapy was not significantly associated with survival (Hazard Ratio [95% CI]: 0.955 [0.572, 1.596], p=0.8618; versus never smokers). Conclusions: Although continued smoking during therapy was not significantly associated with shorter survival, the model developed in this study forms an evidence-based approach to assessing prognosis in advanced stage NSCLC.
- Published
- 2011
- Full Text
- View/download PDF
8. SIDS13: A NEW BREAD WHEAT CULTIVAR
- Author
-
G. Sharawy, M. A. Gouda, M. Zakaria, Wafaa M. El-Awady, S. Abdel-Dayem, A. Menshawy, A. K. Mostafa, S. Hammad, F. Hefnawy, Sabah Abo El-Ela, S. Seleem, W. Abdel-Samad, E. El-Sayed, R. Mitkees, S. Abdel Majeed, A. Moussa, S. El-Sawy, T. Shehab El-Din, S. R. Sabry, M. A. Salem, A. T. Mostafa, Manal A. Hassan, M. Meshref, A. Gad-Allah, Hayam S. Mahgoub, R. A. Ramadan, A. Abo-Warda, A. Gomaa, Najwa Abdel-Fattah, A. Ageez, A. El-Hag, Nadia A. Abdel-Nour, M. Eskandar, A. Hamada, M. S. Shrshar, H. Hendawy, M. A. Moussa, R. Koumbor, A. Sewelam, M. A. Moustafa, Hoda M. M. El-Gharbawy, M. El-Monofy, M. Tawfelies, M. Abo Shereef, A. Abdel-Lattif, Sohair M. Hassan, Magda A. Abdel-Rahman, A. Khattab, M. Y. Mubark, Aza M. Abdel-Al, Iman M. Sadek, H. Ashowh, M. Abdel-Aleem, A. Hagras, M. S. Mahmoud, Enayat Ghanem, A. Morad, A. A. Mahmoud, A. Tammam, M. A. El-Maghraby, S. Kh. Mahmoud, I. A. Amin, N. Hanna, M. A. Khaled, and H. El-Borhamj
- Subjects
Delta ,Agronomy ,Breeding program ,Agriculture ,business.industry ,Yield (wine) ,Sowing ,Cultivar ,Biology ,business ,Rust ,Clearance - Abstract
The new bread wheat cultivar Sids 13 has been developed by Wheat Research Department, Field Crops Research Institute, Agriculture Research Center, Egypt and selected from one of the advanced lines among ICARDA collections grown in wheat breeding program at Sids Agricultural Research Station. The grain yield of the new cultivar Sids 13 was evaluated through 66 experiments at two different levels of yield trials (11 preliminary and 55 advanced yield trials) in the three successive seasons 2004/2005, 2005/2006 and 2006/2007, respectively. The obtained results proved the superiority of the new cultivar Sids 13 as compared to the local commercial cultivars, Giza 168, Sakha 93 and Gemmiza 9 in the main five regions of Egypt, i.e. North Delta, South Delta, Middle Egypt, Upper Egypt and Out Valley. Moreover, stability parameters for grain yield cleared that the newly bread wheat cultivar Sids 13 has better stability parameters in both South Delta and Upper Egypt regions and could be recommended for planting in those regions. Also, the results of rust diseases reactions proved that Sids 13 has high resistance to all tested pathotypes of the three rust diseases under local conditions.
- Published
- 2010
- Full Text
- View/download PDF
9. Primary cardiac Burkitt lymphoma in a child
- Author
-
V. Mialou, S. Di Filippo, M. M. Meshref, Matthias Schell, L. Chalabreysse, P. Marec Bérard, C. Bergeron, F. Sassolas, and C. Chassagne
- Subjects
medicine.medical_specialty ,Chemotherapy ,business.industry ,medicine.medical_treatment ,Primary Cardiac Lymphoma ,Complete remission ,Hematology ,medicine.disease ,Malignancy ,Intracardiac injection ,Surgery ,Lymphoma ,Oncology ,Pediatrics, Perinatology and Child Health ,Usually fatal ,medicine ,Complication ,business - Abstract
Primary cardiac lymphoma (PCL) is a rare and usually fatal malignancy, seldom reported in children. This report describes the case of a 10-year-old boy who presented with multiple intracardiac masses which, when biopsied, proved to be small non-cleaved cell (Burkitt's) lymphoma. The first two cycles of chemotherapy according to the LMB 96 protocol were given under close cardiological supervision, with good response. The treatment was then continued with full-dose chemotherapy, without any cardiological complication. The patient who was treated by chemotherapy alone remains in complete remission 36 months after the end of treatment and can presently be considered as cured, without late cardiac effect.
- Published
- 2004
- Full Text
- View/download PDF
10. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial
- Author
-
Amany Abou Zeid, Saleem Haj-Yahia, Karen C. Redmond, Tarek Mohsen, M. M. Meshref, Nehad Tawfeek, and Olga Ananiadou
- Subjects
Pulmonary and Respiratory Medicine ,Adult ,medicine.medical_specialty ,Palliative care ,Pleural effusion ,Cost effectiveness ,medicine.medical_treatment ,Breast Neoplasms ,Anesthesia, General ,law.invention ,Randomized controlled trial ,law ,Recurrence ,medicine ,Malignant pleural effusion ,Humans ,Prospective Studies ,Prospective cohort study ,Povidone-Iodine ,Pleurodesis ,business.industry ,Thoracic Surgery, Video-Assisted ,Palliative Care ,Insufflation ,General Medicine ,Middle Aged ,medicine.disease ,Thoracostomy ,Surgery ,Pleural Effusion, Malignant ,Dyspnea ,Treatment Outcome ,Talc ,Anesthesia ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Objective: To compare the efficacy, safety, and outcome of thoracoscopic talc poudrage (TTP) versus povidone—iodine pleurodesis (PIP) through a thoracostomy tube as a palliative treatment of pleural effusion due to metastatic breast carcinoma (MBC). Methods: A total of 42 MBC patients were prospectivelyenrolled in a randomized controlled trial. Twenty-two patientsreceived TTP (groupA), whereas 20 patients(group B) underwentpleurodesisbyinstillingpovidone—iodinethrougha thoracostomytube,asabedsideprocedure.Results:Themeanagewas48.2 9.9 (range: 29—64) years and 50.2 7 (range: 32—62) years for groups A and B, respectively (p = ns). At presentation, all patients had moderate to severe dyspnea, NewYork Heart Association(NYHA) > II and MedicalResearch Council(MRC)dyspnea scale3—5. Morbidityin both groupswas low. Post-procedure analgesic requirements due to severe pleuritic chest pain were higher in group A (18% vs 0%, p = 0.2). Four patients in group A (18%) and one in group B (5%) were febrile (>38 8C) within 48 h of the procedure. Both groups achieved good symptom control, with improvement in MRC dyspnea scale (1—3). There were no in-hospital deaths. Post-procedure hospital stay was lower in group B (p = 0.009). The mean progression-free interval was 6.6 (range 3—15) months. At follow-up (mean: 22.6 (range: 8—48) months), recurrence of significant pleural effusion requiring intervention was noted in two and three patients in group A and group B, respectively (p = ns). Conclusion: Povidone—iodine can be consideredasa goodalternativeto TTPto ensure effectivepleurodesisfor patientswith malignantpleural effusiondue to MBC. Thedrug is available, cost effective and safe, can be given through a thoracostomy tube and can be repeated if necessary. # 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
- Published
- 2010
11. Primary cardiac Burkitt lymphoma in a child
- Author
-
M, Meshref, F, Sassolas, M, Schell, L, Chalabreysse, C, Chassagne, V, Mialou, P, Marec Bérard, S, Di Filippo, and C, Bergeron
- Subjects
Heart Neoplasms ,Male ,Echocardiography ,Antineoplastic Combined Chemotherapy Protocols ,Remission Induction ,Humans ,Child ,Burkitt Lymphoma ,Disease-Free Survival - Abstract
Primary cardiac lymphoma (PCL) is a rare and usually fatal malignancy, seldom reported in children. This report describes the case of a 10-year-old boy who presented with multiple intracardiac masses which, when biopsied, proved to be small non-cleaved cell (Burkitt's) lymphoma. The first two cycles of chemotherapy according to the LMB 96 protocol were given under close cardiological supervision, with good response. The treatment was then continued with full-dose chemotherapy, without any cardiological complication. The patient who was treated by chemotherapy alone remains in complete remission 36 months after the end of treatment and can presently be considered as cured, without late cardiac effect.
- Published
- 2004
12. Effect of different doses of prophylactic cranial irradiation in childhood lymphoblastic leukemia on CNS relapse, late cognitive decline and learning disabilities
- Author
-
Mohamed Nasr, Rehab AbdElhai, Nihal Elshazly, and M. M. Meshref
- Subjects
Pediatrics ,medicine.medical_specialty ,Lymphoblastic Leukemia ,Central nervous system ,Cognition ,medicine.anatomical_structure ,Anesthesia ,Learning disability ,medicine ,Latency (engineering) ,medicine.symptom ,Prophylactic cranial irradiation ,Cognitive decline ,Psychology ,Wechsler Intelligence Scale for Children - Abstract
Backgroud: To evaluate the doses of prophylactic cranial irradiation (1800cGy/1200cGy) as regards central nervous system (CNS) relapse, late cognitive abilities and learning disabilities. Subjects and Methods: 42 patients treated for acute lymphoblastic leukemia (ALL) and categorized to be at high risk of relapse were assessed. None of the patients had CNS disease at diagnosis. 28 patients received 1800 cGy prophylactic cranial irradiation and 14 received 1200 cGy. All patients received intrathecal methotrexate as well as high dose methotrexate. Visual and auditory P300 studies were carried out after a mean of 4.6 years follow-up. Visual and auditory evoked potentials were done to assess visual and auditory functions at lower brain levels. Selected subscales of Wechsler Intelligence scale for children namely; similarities, vocabulary, picture completion, design, total performance, total verbal and total IQ and arithmetic abilities were applied to both subgroups. Results: There was no difference in CNS relapse between the two groups (p=0.845). The 1800cGy group showed a significant delay of the visual P300 latency and reduction of the amplitude and delay of auditory P300 latency (p
- Published
- 2013
- Full Text
- View/download PDF
13. A phase II trial of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer
- Author
-
S. Samir, Y. Gouda, T. Abdelhamid, M. Zaki, E. Saad, H. Koheil, A. Kandil, M. M. Meshref, H. Elzawahri, and S. Elmesidy
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Taxane ,Anthracycline ,business.industry ,medicine.medical_treatment ,Phases of clinical research ,Vinorelbine ,medicine.disease ,Metastatic breast cancer ,Gemcitabine ,Regimen ,Internal medicine ,Medicine ,business ,Adjuvant ,medicine.drug - Abstract
1098 Background: MBC (metastatic breast cancer) is among the leading causes of cancer deaths in women worldwide and in Egypt. Gemcitabine has shown synergy with vinorelbine in preclinical models, and has a toxicity profile that is different from vinorelbine. Methods: This was an open-label, single-arm, non-randomised phase II study in patients with locally advanced or MBC who have been previously treated with one anthracycline with/without taxane, based regimen in the adjuvant/neoadjuvant setting. The primary objective of this study was to assess the efficacy of this combination by determining overall response rate. Secondary endpoints were the assessment of the toxicity of gemcitabine in combination with vinorelbine, as well as the time to disease progression, one-year survival. Results: Of the 74 patients enrolled, 72 patients were evaluable for primary treatment outcome (tumor response rates). Overall response rate was 42%. Four patients (6%) had complete response and 26 patients (36%) had partial response. Nineteen patients (26%) had stable disease. Among the 30 patients who had a response to treatment during the study period, the median time to disease progression was 37 weeks (range 1 -60). Median duration of response was 43 weeks (95% CI 31- unestimated). The probability of surviving one year from the Kaplan-Meier estimate for 12 months is 77% (95% CI 64%-86%). Mean percentage of dose intensity of gemcitabine and vinorelbine received was 86% (SD 13%). Mean number of cycles received was 4.4 (SD 1.8). Grade III-IV neutropenia was reported to be 10%, thrombocytopenia was 1.4%, and febrile neutropenia (with documented infection) was 1.4%. As for the clinical toxicities, the most common grade III-IV toxicities were nausea (24%) and diarrhea and stomatitis (11%). Serious clinical adverse events; 5 (7%) hospitalizations for adverse events mainly due to anemia, febrile neutropenia, septic shock and hepatic failure. There were 2 platelet transfusions and 14 RBC transfusions. Conclusions: With a disease control rate of 68%, gemcitabine/vinorelbine demonstrated to have a promising efficacy and at the same time good tolerability in metastatic breast cancer patients. [Table: see text]
- Published
- 2009
- Full Text
- View/download PDF
14. Smoking and prognostic factors in an observational setting in patients with advanced non-small cell lung carcinoma (NSCLC; B9E-AA-B004)
- Author
-
C. Li, S. Qin, W. H. Reece, M. Marek, S. Z. Güçlü, K. Krejcy, M. M. Meshref, Sedat Altug, and Y. Kim
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Lung ,business.industry ,medicine.disease ,medicine.anatomical_structure ,Internal medicine ,medicine ,Carcinoma ,Observational study ,In patient ,Non small cell ,business - Abstract
7588 Background: Previous studies have assessed prognostic factors for advanced NSCLC. This international observational study quantifies the effect of a set of clinically relevant prognostic marker...
- Published
- 2008
- Full Text
- View/download PDF
15. Clinical significance of biochemical markers in prostate cancer
- Author
-
M. Kamal, M. M. Meshref, O. Youssef, and D. Elgayar
- Subjects
Oncology ,PCA3 ,Cancer Research ,medicine.medical_specialty ,business.industry ,urologic and male genital diseases ,medicine.disease ,Prostate cancer ,Internal medicine ,medicine ,Clinical significance ,business ,Biochemical markers - Abstract
16041 Background: Many strategies have been proposed to enhance the ability of PSA in differentiation of Prostate Cancer from BPH. The present study aimed at evaluating the measurement of serum lev...
- Published
- 2008
- Full Text
- View/download PDF
16. Vinorelbine and capecitabine combination as first-line treatment in patients with metastatic breast cancer: Final results of a multicentric trial in Egypt
- Author
-
N. Haddad, Amr Sakr, M. M. Meshref, M. Mahrous, Hesham Elghazaly, and Hesham Tawfik
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Vinorelbine ,medicine.disease ,Metastatic breast cancer ,First line treatment ,Capecitabine ,Internal medicine ,medicine ,In patient ,business ,medicine.drug - Abstract
1125 Background: The efficacy of vinorelbine with capecitabine was shown to be more than just additive in vitro. Moreover, vinorelbine-capecitabine combination demonstrated promising antitumor acti...
- Published
- 2008
- Full Text
- View/download PDF
17. Smoking and prognostic factors in advanced non-small cell lung cancer (NSCLC)
- Author
-
Y. Kim, C. Li, K. Krejcy, S. Qin, M. Marek, S. Z. Güçlü, W. H. Reece, M. M. Meshref, and Sedat Altug
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,business.industry ,Internal medicine ,medicine ,non-small cell lung cancer (NSCLC) ,Observational study ,Intensive care medicine ,business ,medicine.disease - Abstract
18048 Background: The aim of this prospective, multi-country, observational study (B9E-AA-B004) is to estimate the effect of prognostic factors, including continued smoking during therapy, on treatment outcomes in patients (pts) with advanced NSCLC receiving first- line chemotherapy with a gemcitabine (gem)-platinum combination as part of their routine care. Methods: Major eligibility criteria included: tissue diagnosis of advanced stage IIIB/IV NSCLC not amenable to curative surgery/radiotherapy; no prior chemotherapy; ECOG performance status (PS) 0 or 1; and written informed consent. A predictive model was constructed and validated by splitting the data at random by centre into two datasets in a ratio of 3:1 Construction:Validation. The primary and secondary endpoints are the effect of prognostic factors on survival and selected adverse events (AEs), respectively. The association of smoking with outcomes was tested in the Construction dataset. Results: This interim analysis to assess the effect of prognostic factors on AEs occurred when all pts had completed treatment. 1214 pts were enrolled: 75.1% male; mean age 60.5 yr, range 23–86 yr; 57.1% Stage IV; 66.2% PS 1; 69.4% received gem-cis, 30.5% gem-carb; 25.7% had never smoked, 70.8% had ever smoked and 11.2% continued smoking during therapy. 22.0% of pts had =1 AE. After variable selection in the Construction database (891 pts) the following factors were associated with an AE possibly related to therapy: disease stage (IV vs III, odds ratio (OR) =1.48, p=0.034), weight loss >10% (OR=0.60, p=0.017), age ( [Table: see text]
- Published
- 2007
- Full Text
- View/download PDF
18. Bifocal Intracranial germinoma (BIG): Is there a place for localized radiation?
- Author
-
Yves Perel, Pascal Chastagner, M. C. Baranzelli, Jean-Claude Gentet, Claire Alapetite, M. M. Meshref, C. Patte, and D. Frappaz
- Subjects
Cancer Research ,medicine.medical_specialty ,Pathology ,Chemotherapy ,Ifosfamide ,Germinoma ,business.industry ,medicine.medical_treatment ,medicine.disease ,Craniospinal Irradiation ,medicine.anatomical_structure ,Oncology ,Intracranial Germinoma ,medicine ,Non metastatic ,Radiology ,business ,Etoposide ,Germ cell ,medicine.drug - Abstract
8548 BACKGROUND Bifocal tumours represent 7–12 % of primary cerebral germ cell tumours and are mostly germinomas. The treatment of non metastatic germinomas includes either craniospinal irradiation (CSI) or chemotherapy with focal RT. BIG still represent a challenge. Should they be treated as localized or metastatic disease? This study aims to evaluate the outcome of treatment of BIG treated by chemotherapy followed by localized radiation to tumour bed in non metastatic disease METHODS The data of 118 patients included from 1990–1999 in the SFOP-TGM-TC 90–92 protocol for intracranial germ cell tumours were reviewed. The treatment of patients with germinomas (80 patients) included 2 cycles of alternating carboplatine/Etoposide and Ifosfamide /Etoposide followed by focal RT (40 Gy) delivered to initial target in localised diseases or CSI in metastatic patients. RESULTS 12/118 germ cell tumours had bifocal disease: 2/38 in the secreting group, 10/80 in the non secreting germinoma group. Two of these 10 were ...
- Published
- 2004
- Full Text
- View/download PDF
19. AERIAL RADIOMETRY OF EL ALAMEIN OILFIELD, EGYPT, U.A.R.*
- Author
-
E. M. El Shazly, A. A. Ammar, W. M. Meshref, M. L. Meleik, and K. M. Fouad
- Subjects
Geophysics ,Geochemistry and Petrology ,Mineralogy ,Radiometry ,Radiometric dating ,Geology - Abstract
Total gamma airborne radiometric survey of El Alamein area in the Western Desert has been carried out by the Atomic Energy Establishment. The flight lines are directed north-south with 500 m spacing, while the ground clearance is about 50 m. Superimposition of the radioactivity profiles over El Alamein Oilfield shows a general decrease of gamma radiation in the central part of the structure framed by zones of relatively higher values. The aerial radioactivity of El Alamein Oilfield is described and it is correlated with some reported radiometric characteristics of other oil bearing structures. The distribution of aeroradiometric measurements over El Alamein Oilfield and its environment has been found to be lognormal.
- Published
- 1969
- Full Text
- View/download PDF
20. A phase II study of gemcitabine combined with vinorelbine as first-line chemotherapy for metastatic breast cancer
- Author
-
Yasser Goda, M. M. Meshref, Ebtesam Saad, Thoraya Abdelhamid, Samir Shehata, Salah El-Mesidi, Heba Elzawhri, Alaa Abdelrahman Kandeel, Hanaa Koheil, and Mounir Zaki
- Subjects
Adult ,Oncology ,medicine.medical_specialty ,Breast Neoplasms ,Neutropenia ,Vinblastine ,Vinorelbine ,lcsh:RC254-282 ,Deoxycytidine ,Breast cancer ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Anthracyclines ,lcsh:RC633-647.5 ,business.industry ,lcsh:Diseases of the blood and blood-forming organs ,General Medicine ,Hematology ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Survival Analysis ,Gemcitabine ,Metastatic breast cancer ,Regimen ,Treatment Outcome ,Tolerability ,Female ,business ,Febrile neutropenia ,medicine.drug - Abstract
BACKGROUND AND OBJECTIVES There is an unmet need for new combination treatments, especially for aggressive, visceral, and high tumor burden metastatic breast cancer. Gemcitabine (GEM) has shown synergy with vinorelbine (VRL) in preclinical models, and has a toxicity profile that is different from VRL, another recently approved cytotoxic drug that seems to be effective in the treatment of breast cancer. METHODS We studied the efficacy and side effects of the GEM-VRL combination as first-line chemotherapy in patients in an open-label, single arm, phase II study in patients with locally advanced or metastatic breast cancer who had been previously treated with an anthracycline-based regimen in the adjuvant/neoadjuvant setting. RESULTS Of the 74 patients enrolled, 72 patients were evaluable for the primary treatment outcome (tumor response rates). Four patients (6%) had a complete response and 26 patients (36%) had a partial response. Nineteen patients (26%) had stable disease. The median time to disease progression was 37 weeks (range, 1-60 weeks). Median duration of response was 43 weeks (range, 8.6 to 55 weeks) and one-year survival was 77% (95% confidence interval, 64% to 86%). Grade 3-4 neutropenia without fever was reported in 10% of patients, thrombocytopenia in 1%, and febrile neutropenia in 11%. The most common clinical grade 3-4 toxicities were nausea (24%) and diarrhea and stomatitis (11% each). Hospitalizations for adverse events mainly due to anemia, febrile neutropenia, septic shock and hepatic failure occured in 7%. CONCLUSION With an overall response rate of 42%, the GEM-VRL combination had promising efficacy and good tolerability in metastatic breast cancer patients.
- Full Text
- View/download PDF
21. Tectonic Evolution of Abu Gharadig Basin: ABSTRACT
- Author
-
W. M. Meshref and A. E. H. Beleity
- Subjects
Tectonics ,Paleontology ,Fuel Technology ,Geochemistry and Petrology ,Earth and Planetary Sciences (miscellaneous) ,Energy Engineering and Power Technology ,Geology ,Structural basin - Published
- 1988
- Full Text
- View/download PDF
22. History of head trauma and the risk of multiple sclerosis: A systematic review and meta-analysis.
- Author
-
Abouelmagd ME, AbdelMeseh M, Hassan AA, Ali MA, Mohamed RG, Mady A, Hindawi MD, and Meshref M
- Subjects
- Humans, Multiple Sclerosis epidemiology, Multiple Sclerosis etiology, Craniocerebral Trauma epidemiology, Craniocerebral Trauma complications
- Abstract
Background: Multiple sclerosis (MS) is a chronic disease of the central nervous system with unclear etiology involving genetic, environmental, and immunological factors. The potential link between head trauma and MS is controversial, with conflicting evidence. This systematic review and meta-analysis aim to assess the risk of developing MS following head trauma., Methods: A systematic search of electronic databases was conducted, including studies that investigated the risk of MS in individuals with a history of head trauma compared to those without. Observational studies, including cohort and case-control designs, were included. Data synthesis was conducted using RevMan software. GRADE was used to assess the certainty of evidence., Results: Fifteen studies comprising 1,619,640 participants were included in the meta-analysis. The overall odds of developing MS were significantly higher in the head trauma group compared to the control group (OR = 1.41;95 % CI = [1.23, 1.61]; P < 0.00001; I
2 = 62 %). Sensitivity analyses based on the number of participants and quality further supported our results. Subgroup analysis showed that results remained consistent across different head trauma identification methods (P = 0.92), early age head trauma and head trauma defined as TBI, or concussion were also significant predictors of MS (P < 0.0001). Analysis of the number of hits suggested a dose-response relationship between the number of head injuries and the risk of MS. According to the GRADE, all outcomes were classified as low or very low certainty of the evidence., Conclusion: This meta-analysis suggests that a history of head trauma may be associated with an increased risk of developing MS. Further research is warranted to support our findings and explore the mechanisms linking head trauma to MS., Competing Interests: Declaration of competing interest The authors declare that they have no conflicts of interest., (Copyright © 2024 Elsevier B.V. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
23. Effect of Everolimus on Prognosis of Neurofibromatosis Type 1 Lesions: A Systematic Review and Meta Analysis.
- Author
-
Ibrahim IA, Abdelkader RE, Nada AH, Younes S, Hanen G, Shahwan G, Hamad M, Meshref M, and Nashwan AJ
- Subjects
- Humans, Prognosis, Treatment Outcome, Antineoplastic Agents therapeutic use, Everolimus therapeutic use, Everolimus administration & dosage, Neurofibromatosis 1 drug therapy
- Abstract
Purpose: This study addresses the effectiveness of oral everolimus in treating various malignancies associated with Neurofibromatosis Type 1 (NF1). The purpose is to determine whether everolimus reduces lesion size in NF1 patients, considering the controversial findings from previous clinical trials. The scientific hypotheses and questions involve evaluating the impact of everolimus on NF1-associated lesions and understanding the variability in treatment outcomes., Methods: A systematic review and meta-analysis were conducted following PRISMA and Cochrane Collaboration guidelines. The study included four-phase II, single-arm, nonrandomized trials investigating the effect of oral everolimus on NF1-associated lesion size. The search covered multiple databases, and data extraction involved evaluating studies for inclusion criteria and assessing quality using the Cochrane Collaboration's Risk of Bias in Nonrandomized Studies tool. Statistical analysis utilized Open Meta(Analyst)., Findings: The search yielded 388 studies, with 10 selected for full-text review and four included in the final analysis. The quality of the studies ranged from low to moderate. The meta-analysis indicated no observed heterogeneity (I^2 = 0%), and the overall estimate suggested no significant reduction in NF1-associated lesion size with everolimus (P = 0.069)., Implications: The findings reveal a varied and inconsistent picture of everolimus efficacy in NF1 treatment. The study highlights the need for personalized approaches, considering individual genetic and clinical differences. The limitations, including small sample sizes and nonrandomized trials, call for larger, more standardized research efforts. The study emphasizes ongoing trials and the importance of future research in understanding predictors of everolimus response and optimizing treatment strategies for NF1 patients., Conclusion: While everolimus shows promise in reducing lesion size in a subset of NF1 patients, the study cannot draw conclusive results due to limitations in the included studies. Ongoing, adequately powered trials are crucial for advancing the evidence base and informing the potential role of everolimus in NF1 treatment., Others: There was no funding for this review and no conflicts of interest., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
24. Prevalence and characteristics of headache among medical students in Egypt: a multicentric cross-sectional study.
- Author
-
Mohamed RG, Sarhan K, Kamel B, Almetwaly RM, Fouda EE, Meshref M, Bioumy S, Alemam D, and Ahmed HA
- Abstract
Background: Headaches are one of the most common neurological disorders, ranging in severity from mild discomfort to a severe, debilitating condition. Headaches are particularly prevalent among medical students, which can be attributed to various factors such as psychological stressors, extensive studying, long hours of clinical rotations and high-pressure examination. This study aims to ascertain the prevalence of different types of headaches, along with analysing their associated clinical characteristics among medical students in Egypt., Methods: A multicentric, descriptive questionnaire-based cross-sectional study was conducted across five governmental faculties of medicine in Egypt from November 2022 to March 2023. Using a multistage random sampling method, 600 undergraduate students were selected to participate. Headache was diagnosed based on the International Classification of Headache Disorders., Results: A total of 493 responses were included in the analysis; the prevalence of headache disorder was 264 (53.5%), with tension-type headaches (TTH) frequent episodic being the highest 89 (33.7%), while TTH chronic and migraine with aura were the least prevalent, accounting for 10 (3.8%) and 31 (11.7%), respectively. Women exhibited a higher overall headache prevalence (69.4%) compared with men (44.4%). A positive family history was found in 120 (45.5%) of students with headache. Lack of sleep and stress were the most frequently reported potential triggers for headaches. Out of 264 medical students, 171 (65%) took analgesics. Only 42 (24.6%) had a medical consultation, while most students 129 (75.4%) took over-the-counter medications., Conclusion: Notably, headaches were prevalent in 264 (53.5%) of the respondents. TTH frequent and infrequent emerged as the most common headaches among medical students, followed by migraine without aura then migraine with aura. Participants were statistically different according to sex, faculty, academic year and living conditions. Alarmingly, despite the substantial prevalence, only 42 (24.6%) students sought medical consultation., Competing Interests: None declared., (Copyright © Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
25. Incidence and risk factors of venous thromboembolism in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis.
- Author
-
Hamad AA, Alkhawaldeh IM, Abbas A, Elaraby A, and Meshref M
- Subjects
- Humans, Incidence, Risk Factors, Male, Female, Amyotrophic Lateral Sclerosis epidemiology, Amyotrophic Lateral Sclerosis complications, Venous Thromboembolism epidemiology, Venous Thromboembolism etiology
- Abstract
Aims: This systematic review and meta-analysis aimed to determine the annual incidence rate of venous thromboembolism (VTE) and identify risk factors of VTE in amyotrophic lateral sclerosis (ALS) patients., Methods: A comprehensive search of three databases was conducted up to April 8, 2024, to identify longitudinal studies reporting VTE incidence in ALS patients. The included studies were either prospective or retrospective, following up with ALS patients. Quality assessment was performed using the NIH tool for observational cohort studies. Meta-analysis was conducted using Open Meta Analyst, employing a random-effect model. Subgroup, Meta-regression, and sensitivity analyses were also carried out., Results: Our analysis included eight studies comprising a total of 26,758 ALS patients that met the inclusion criteria. The pooled annual incidence of VTE across all studies was found to be 22 cases per 1,000 person-year (95% CI = 18 to 27). Subgroup analysis revealed that the annual incidence of VTE in males was 19 cases per 1,000 person-year (95% CI = 15 to 22), while in females, it was 20 cases per 1,000 person-year (95% CI = 16 to 25). Leave-one-out analysis demonstrated that the incidence ranged from 21 to 28 cases per 1,000 person-year when excluding each study individually. Meta-regression analysis did not find a significant association between age and the risk of VTE (P = 0.079). Based on the included studies, risk factors of VTE in ALS patients included a history of VTE, non-invasive ventilation, immobility, and decreased functional status., Conclusion: Patients with ALS face a higher risk of developing VTE compared to individuals of the same age. These findings underscore the importance of implementing preventive measures and closely monitoring VTE in ALS patients.
- Published
- 2024
- Full Text
- View/download PDF
26. Safety and efficacy of unilateral focused ultrasound pallidotomy on motor complications in Parkinson's disease (PD): a systematic review and meta-analysis.
- Author
-
Abbas A, Hassan MA, Shaheen RS, Hussein A, Moawad MHED, Meshref M, and Raslan AM
- Subjects
- Humans, Treatment Outcome, Pallidotomy methods, Parkinson Disease surgery
- Abstract
To systematically review and conduct a meta-analysis to evaluate the safety and efficacy of the unilateral focused ultrasound (FUS) pallidotomy on motor complications in Parkinson's disease (PD) patients. A comprehensive search strategy was implemented through August 15, 2023, and updated on February 13, 2024, across six databases, identifying studies relevant to unilateral focused ultrasound pallidotomy and PD. Eligibility criteria included observational studies, clinical trials, and case series reporting on the impact of the intervention on motor complications in PD patients. The screening and data extraction were done by two independent reviewers. Risk of bias assessment utilized appropriate tools for different study designs. Statistical analysis involved narrative synthesis and meta-analysis. Subgroup analyses and leave-one-out analyses were performed. Five studies were included in our study, involving 112 PD patients undergoing FUS pallidotomy. UPDRS-II analysis revealed a significant improvement from baseline (mean difference (MD): -3.205, 95% CI: -4.501, -1.909, P < 0.001). UPDRS-III overall change was significant (MD: -10.177, 95% CI: [-12.748, -7.606], P < 0.001). UPDRS-IV showed a significant change from baseline (MD: -5.069, 95% CI: [-5.915, -4.224], P < 0.001). UDysRS demonstrated a significant overall improvement (MD: -18.895, 95% CI: [-26.973, -10.818], P < 0.001). The effect of FUS pallidotomy on motor complications in PD patients was effective, with a significant decrease in the UPDRS and UDysRS, reflecting improvement. The incidence of adverse events (headaches, pin-site pain, difficulty walking, and sonication-related head pain) of the FUS pallidotomy was not statistically significant, indicating its safety., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
27. Exploring the Mechanisms and Therapeutic Approaches of Mitochondrial Dysfunction in Alzheimer's Disease: An Educational Literature Review.
- Author
-
Moawad MHED, Serag I, Alkhawaldeh IM, Abbas A, Sharaf A, Alsalah S, Sadeq MA, Shalaby MMM, Hefnawy MT, Abouzid M, and Meshref M
- Abstract
Alzheimer's disease (AD) presents a significant challenge to global health. It is characterized by progressive cognitive deterioration and increased rates of morbidity and mortality among older adults. Among the various pathophysiologies of AD, mitochondrial dysfunction, encompassing conditions such as increased reactive oxygen production, dysregulated calcium homeostasis, and impaired mitochondrial dynamics, plays a pivotal role. This review comprehensively investigates the mechanisms of mitochondrial dysfunction in AD, focusing on aspects such as glucose metabolism impairment, mitochondrial bioenergetics, calcium signaling, protein tau and amyloid-beta-associated synapse dysfunction, mitophagy, aging, inflammation, mitochondrial DNA, mitochondria-localized microRNAs, genetics, hormones, and the electron transport chain and Krebs cycle. While lecanemab is the only FDA-approved medication to treat AD, we explore various therapeutic modalities for mitigating mitochondrial dysfunction in AD, including antioxidant drugs, antidiabetic agents, acetylcholinesterase inhibitors (FDA-approved to manage symptoms), nutritional supplements, natural products, phenylpropanoids, vaccines, exercise, and other potential treatments., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
28. Correlation of silent brain infarcts and leukoaraiosis in middle-aged ischemic stroke patients: a retrospective study.
- Author
-
Abdulsalam MF, Shaheen N, Shaheen A, Alabdallat YJ, Ramadan A, Meshref M, Mansour FM, Abed E, Fayed AI, Zaki MA, El-Adawy AF, Flouty O, and Hamed M
- Abstract
Background: Cerebrovascular diseases of the brain are usually defined by transient ischemic attacks and strokes. However, they can also cause brain injuries without neurological events. Silent brain infarcts (SBI) and leukoaraiosis are symptoms of both vascular and neurological abnormalities. This study aims to investigate the association between SBI, leukoaraiosis, and middle-aged patients with ischemic stroke., Methods: A single-center retrospective study of 50 middle-aged, ischemic stroke patients were studied from November 2022 and May 2023. The patients were divided into two groups based on the presence or absence of leukoaraiosis. History taking, physical examination, brain CT scan, and MRI were all part of the diagnostic process. Metabolic syndrome (MetS) was also assessed through various factors. The statistical analysis included descriptive statistics, logistic regression analysis, and chi-square test., Results: Out of the cohort comprising 50 patients, characterized by a mean age of 52.26 years (SD 5.29), 32 were male, constituting 64% of the sample. Among these patients, 26 individuals exhibited leukoaraiosis, with 17 of them (65.4%) also presenting with SBI. Moreover, within this cohort, 22 patients were diagnosed with MetS, representing 84.6% of those affected. The Multivariate logistic regression analysis showed a strong and independent association between leukoaraiosis and SBI. Individuals with leukoaraiosis were nearly five times more likely to have SBI compared to those without leukoaraiosis., Conclusion: The study highlights leukoaraiosis as a significant risk factor for SBI, alongside MetS. Advanced imaging techniques have facilitated their detection, revealing a higher prevalence among stroke patients, particularly associated with age and hypertension. Further research is needed to fully understand their complex relationship and develop better management strategies for cerebrovascular diseases, ultimately improving patient outcomes., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Abdulsalam, Shaheen, Shaheen, Alabdallat, Ramadan, Meshref, Mansour, Abed, Fayed, Zaki, El-Adawy, Flouty and Hamed.)
- Published
- 2024
- Full Text
- View/download PDF
29. Dual antiplatelet therapy versus intravenous tissue plasminogen activator with acute minor ischemic stroke: A systematic review and meta-analysis of safety and efficacy.
- Author
-
Abbas A, Hamad AA, El Din Moawad MH, Ewis DK, Youssef RA, Hamouda H, Hassan MA, Aladawi M, Elfil M, Meshref M, and Al-Mufti F
- Subjects
- Humans, Treatment Outcome, Risk Factors, Male, Female, Aged, Middle Aged, Risk Assessment, Disability Evaluation, Administration, Intravenous, Recovery of Function, Observational Studies as Topic, Aged, 80 and over, Ischemic Stroke drug therapy, Ischemic Stroke diagnosis, Ischemic Stroke mortality, Tissue Plasminogen Activator adverse effects, Tissue Plasminogen Activator administration & dosage, Fibrinolytic Agents adverse effects, Fibrinolytic Agents administration & dosage, Platelet Aggregation Inhibitors adverse effects, Platelet Aggregation Inhibitors administration & dosage, Dual Anti-Platelet Therapy adverse effects, Thrombolytic Therapy adverse effects, Thrombolytic Therapy mortality
- Abstract
Objectives: To compare the safety and efficacy of Dual Antiplatelet Therapy (DAPT) and Intravenous (IV) Tissue Plasminogen Activator (t-PA) in minor Acute Ischemic Stroke (AIS)., Materials and Methods: Following Cochrane and PRISMA guidelines, we analyzed observational studies and clinical trials comparing DAPT and IV t-PA in patients with minor AIS. Databases included PubMed, Scopus, and Web of Science. Data extraction included study characteristics, patient demographics, and analyzed outcomes. RevMan 5.3 and OpenMetaAnalyst 2021 were used to analyze the data and assess heterogeneity, respectively. The risk of bias was determined using RoB 2.0 and the Newcastle-Ottawa scale., Results: This meta-analysis included five studies with 3,978 DAPT-treated patients and 2,224 IV t-PA-treated patients. We found no significant differences in achieving modified Rankin scale (mRS) scores of 0-1 (OR 1.11, 95 % CI: 0.79, 1.55, p = 0.56) and 0-2 (OR 0.90, 95 % CI: 0.61, 1.31, p = 0.57), as well as combined mRS scores (OR 1.05, 95 % CI: 0.82, 1.34, p = 0.72). Similarly, there were no significant disparities between the two treatment groups in NIHSS score change from baseline (MD 0.32, 95 % CI: -0.35, 0.98, p = 0.35) and in mortality rates (OR 0.87, 95 % CI: 0.26, 2.93, p = 0.83). Notably, in comparison to the IV t-PA group, the DAPT group exhibited a significantly lower incidence of bleeding (OR 0.31, 95 % CI: 0.14, 0.69, p = 0.004) and symptomatic intracranial hemorrhage (sICH) (OR 0.10, 95 % CI: 0.04, 0.26, p < 0.00001)., Conclusions: Our meta-analysis found no significant differences in efficacy between DAPT and IV t-PA. However, DAPT demonstrated a significantly lower risk of sICH and bleeding compared with IV t-PA., Competing Interests: Declaration of competing interest No conflict of interest., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
30. Efficacy of Cerebellar Transcranial Magnetic Stimulation in Treating Essential Tremor: A Randomized, Sham-Controlled Trial.
- Author
-
El-Adawy AFI, Reda MAMG, Ahmed AM, Rashad MH, Zaki MA, Mohamed MT, Hassan MAS, Abdulsalam MF, Hassan AM, Mohamed AF, Fayed AI, Meshref M, Mansour FM, Sarhan AE, Elsheshiny AH, and Abed E
- Abstract
Background and Purpose: Repetitive transcranial magnetic stimulation (rTMS) of the cerebellar hemisphere represents a new option in treating essential tremor (ET) patients. We aimed to determine the efficacy of cerebellar rTMS in treating ET using different protocols regarding the number of sessions, exposure duration, and follow-up duration., Methods: A randomized sham-controlled trial was conducted, in which 45 recruit patients were randomly allocated to 2 groups. The first (active group) comprised 23 patients who were exposed to 12 sessions of active rTMS with 900 pulses of 1-Hz rTMS at 90% of the resting motor threshold daily on each side of the cerebellar hemispheres over 4 weeks. The second group (sham group) comprised 22 patients who were exposed to 12 sessions of sham rTMS. Both groups were reassessed at baseline and after 1 day, 1 month, 2 months, and 3 months using the Fahn-Tolosa-Marin tremor-rating scale (FTM)., Results: Demographic characteristics did no differ between the two groups. There were significant reductions both in FTM subscores A and B and in the FTM total score in the active-rTMS group during the period of assessment and after 3 months ( p =0.031 and 0.011, respectively). However, subscore C did not change significantly from baseline when assessed at 2 and 3 months ( p =0.073 and 0.236, respectively). Furthermore, the global assessment score was significantly higher in the active-rTMS group ( p >0.001)., Conclusions: Low-frequency rTMS over the cerebellar cortex for 1 month showed relative safety and long-lasting efficacy in patients with ET. Further large-sample clinical trials are needed that include different sites of stimulation and longer follow-ups., Competing Interests: The authors have no potential conflicts of interest to disclose., (Copyright © 2024 Korean Neurological Association.)
- Published
- 2024
- Full Text
- View/download PDF
31. The Role of RIN3 Gene in Alzheimer's Disease Pathogenesis: a Comprehensive Review.
- Author
-
Meshref M, Ghaith HS, Hammad MA, Shalaby MMM, Ayasra F, Monib FA, Attia MS, Ebada MA, Elsayed H, Shalash A, and Bahbah EI
- Subjects
- Humans, Animals, Guanine Nucleotide Exchange Factors genetics, Guanine Nucleotide Exchange Factors metabolism, Amyloid beta-Peptides metabolism, Brain metabolism, Brain pathology, Alzheimer Disease genetics, Alzheimer Disease metabolism
- Abstract
Alzheimer's disease (AD) is a globally prevalent form of dementia that impacts diverse populations and is characterized by progressive neurodegeneration and impairments in executive memory. Although the exact mechanisms underlying AD pathogenesis remain unclear, it is commonly accepted that the aggregation of misfolded proteins, such as amyloid plaques and neurofibrillary tau tangles, plays a critical role. Additionally, AD is a multifactorial condition influenced by various genetic factors and can manifest as either early-onset AD (EOAD) or late-onset AD (LOAD), each associated with specific gene variants. One gene of particular interest in both EOAD and LOAD is RIN3, a guanine nucleotide exchange factor. This gene plays a multifaceted role in AD pathogenesis. Firstly, upregulation of RIN3 can result in endosomal enlargement and dysfunction, thereby facilitating the accumulation of beta-amyloid (Aβ) peptides in the brain. Secondly, RIN3 has been shown to impact the PICLAM pathway, affecting transcytosis across the blood-brain barrier. Lastly, RIN3 has implications for immune-mediated responses, notably through its influence on the PTK2B gene. This review aims to provide a concise overview of AD and delve into the role of the RIN3 gene in its pathogenesis., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
32. Masitinib as a neuroprotective agent: a scoping review of preclinical and clinical evidence.
- Author
-
Hamad AA, Amer BE, Hawas Y, Mabrouk MA, and Meshref M
- Subjects
- Humans, Animals, Protein Kinase Inhibitors pharmacology, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use, Benzamides pharmacology, Benzamides therapeutic use, Thiazoles pharmacology, Thiazoles therapeutic use, Piperidines pharmacology, Piperidines therapeutic use, Pyridines pharmacology, Pyridines therapeutic use
- Abstract
Objectives: Masitinib, originally developed as a tyrosine kinase inhibitor for cancer treatment, has shown potential neuroprotective effects in various neurological disorders by modulating key pathways implicated in neurodegeneration. This scoping review aimed to summarize the current evidence of masitinib's neuroprotective activities from preclinical to clinical studies., Methods: This scoping review was conducted following the guidelines described by Arksey and O'Malley and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The inclusion criteria covered all original studies reporting on the neuroprotective effects of masitinib, including clinical studies, animal studies, and in vitro studies., Results: A total of 16 studies met the inclusion criteria and were included in the review. These comprised five randomized controlled trials (RCTs), one post-hoc analysis study, one case report, and nine animal studies. The RCTs focused on Alzheimer's disease (two studies), multiple sclerosis (two studies), and amyotrophic lateral sclerosis (one study). Across all included studies, masitinib consistently demonstrated neuroprotective properties. However, the majority of RCTs reported concerns regarding the safety profile of masitinib. Preclinical studies revealed the neuroprotective mechanisms of masitinib, which include inhibition of certain kinases interfering with cell proliferation and survival, reduction of neuroinflammation, and exhibition of antioxidant activity., Conclusion: The current evidence suggests a promising therapeutic benefit of masitinib in neurodegenerative diseases. However, further research is necessary to validate and expand upon these findings, particularly regarding the precise mechanisms through which masitinib exerts its therapeutic effects. Future studies should also focus on addressing the safety concerns associated with masitinib use., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
33. L-2-hydroxyglutaric aciduria: a report of clinical, radiological, and genetic characteristics of two siblings from Egypt.
- Author
-
Fayed AI, Mohamed MT, Abed E, Meshref M, and Ali Mahmoud A
- Subjects
- Child, Humans, Brain diagnostic imaging, Brain pathology, Brain Diseases, Metabolic genetics, Brain Diseases, Metabolic diagnostic imaging, Brain Diseases, Metabolic diagnosis, Brain Diseases, Metabolic, Inborn genetics, Brain Diseases, Metabolic, Inborn diagnosis, Brain Diseases, Metabolic, Inborn diagnostic imaging, Egypt, Magnetic Resonance Imaging, Alcohol Oxidoreductases genetics, Siblings
- Abstract
L-2-hydroxyglutaric aciduria (L-2-HGA) is a rare autosomal recessive disease characterized by elevated levels of hydroxyglutaric acid in the body fluids and brain with abnormal white matter. We present two siblings with psychomotor retardation and quadriparesis. Their brain imaging showed diffuse bilateral symmetrical involvement of the cerebral cortex, white matter, basal ganglia and cerebellum. The whole exome sequence studies revealed a homozygous likely pathogenic variant on chromosome 14q22.1 (NM_024884.2: c.178G > A; pGly60Arg) in the gene encoding for L-2-hydroxyglutarate dehydrogenase (L2HGDH) (OMIM #236792). Therefore, using the L2HGDH gene study is beneficial for L2HGA diagnosis.
- Published
- 2024
- Full Text
- View/download PDF
34. Prevalence and correlates of fatigue in amyotrophic lateral sclerosis: A systematic review and meta-analysis.
- Author
-
Hamad AA, Amer BE, Abbas NB, Alnajjar AZ, and Meshref M
- Subjects
- Humans, Prevalence, Quality of Life, Fatigue etiology, Fatigue complications, Amyotrophic Lateral Sclerosis complications, Amyotrophic Lateral Sclerosis epidemiology
- Abstract
Objectives: This systematic review and meta-analysis aimed to determine the frequency and correlates of fatigue in patients with amyotrophic lateral sclerosis (ALS)., Methods: Three databases were searched up to 2nd May 2023 to identify studies reporting fatigue frequency in ALS. Studies included had to identify ALS patients through one of ALS diagnostic criteria and measure fatigue by a validated tool with a specific cut-off value. Meta-analysis was conducted using RStudio's "meta" package with a random-effects model. Subgroup analyses and meta-regression explored the relationship between fatigue frequency in ALS and different covariates., Results: Eleven studies, compromising 1072 patients, met the inclusion criteria and were included in our analysis. The pooled frequency of fatigue across all studies was 48% (95% CI = 40% to 57%). Our subgroup analysis based on the ALSFRS-R revealed a higher frequency of fatigue in studies with lower scores (< 30) compared to those with higher scores (≥ 30), with a pooled frequency of 62% (95% CI = 43% to 79%) and 43% (95% CI = 37% to 49%), respectively. Also, the meta-regression analysis showed a significant negative association between fatigue and ALSFRS-R mean (P = 0.02). The included studies reported an association between fatigue and lower functional status and poorer quality of life in patients with ALS., Conclusion: Our findings suggest that fatigue is prevalent in almost half of ALS patients and is associated with lower functional status and poorer quality of life, highlighting the importance of assessing and managing fatigue in ALS patients., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
35. Association of serum leptin and ghrelin levels with smoking status on body weight: a systematic review and meta-analysis.
- Author
-
Shaheen N, Shaheen A, Diab RA, Saad AM, Abdelwahab OA, Soliman S, Hefnawy MT, Ramadan A, Meshref M, and Nashwan AJ
- Abstract
Background and Aims: Smoking cigarettes is a major global health problem that affects appetite and weight. The aim of this systematic review was to determine how smoking affected plasma leptin and ghrelin levels., Methods: A comprehensive search of PubMed, Scopus, Web of Science, and Ovid was conducted using a well-established methodology to gather all related publications., Results: A total of 40 studies were included in the analysis of 11,336 patients. The overall effect showed a with a mean difference (MD) of -1.92[95%CI; -2.63: -1.20] and p = 0.00001. Subgroup analysis by study design revealed significant differences as well, but with high heterogeneity within the subgroups ( I
2 of 82.3%). Subgroup by sex showed that there was a significant difference in mean difference between the smoking and non-smoking groups for males (MD = -5.75[95% CI; -8.73: -2.77], p = 0.0002) but not for females (MD = -3.04[95% CI; -6.6:0.54], p = 0.10). Healthy, pregnant, diabetic and CVD subgroups found significant differences in the healthy (MD = -1.74[95% CI; -03.13: -0.35], p = 0.01) and diabetic (MD = -7.69[95% CI, -1.64: -0.73], p = 0.03). subgroups, but not in the pregnant or cardiovascular disease subgroups. On the other hand, the meta-analysis found no statistically significant difference in Ghrelin serum concentration between smokers and non-smokers (MD = 0.52[95% CI, -0.60:1.63], p = 0.36) and observed heterogeneity in the studies ( I2 = 68%)., Conclusion: This study demonstrates a correlation between smoking and serum leptin/ghrelin levels, which explains smoking's effect on body weight., Systematic Review Registration: https://www.crd.york.ac.uk/ prospero/display_record.php, identifier (Record ID=326680)., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Shaheen, Shaheen, Diab, Saad, Abdelwahab, Soliman, Hefnawy, Ramadan, Meshref and Nashwan.)- Published
- 2023
- Full Text
- View/download PDF
36. Restless legs syndrome in multiple sclerosis patients: Prevalence, impact, and association with disease-modifying therapies in a Saudi Arabian pilot study.
- Author
-
Younis H, Shaheen N, Meshref M, Shaheen A, Elmasry M, Ramadan A, Nashwan AJ, Hamed M, and El-Adawy AF
- Subjects
- Humans, Saudi Arabia epidemiology, Pilot Projects, Prevalence, Sleepiness, Cross-Sectional Studies, Fingolimod Hydrochloride, Severity of Illness Index, Restless Legs Syndrome drug therapy, Restless Legs Syndrome epidemiology, Multiple Sclerosis complications, Multiple Sclerosis drug therapy, Multiple Sclerosis epidemiology
- Abstract
Background: Restless legs syndrome (RLS) emerges as a notable sleep disorder characterized by distressing sensations within the lower extremities. Its prevalence appears to be higher among patients afflicted with multiple sclerosis (MS) compared to the general population. Despite this observation, the understanding of the intricacies of RLS and its repercussions within the context of MS patients in Saudi Arabia remains limited., Methods: Employing a cross-sectional design, a comprehensive investigation was undertaken at King Fahad Armed Forces Hospital in Jeddah, Saudi Arabia, spanning from November 2021 to March 2022. A cohort of 66 individuals diagnosed with MS was recruited and subjected to an assessment for RLS employing the revised diagnostic criteria outlined by the International Restless Legs Syndrome Study Group (IRLSSG). Furthermore, the Pittsburgh Sleep Quality Index, Epworth Sleepiness Scale, and Sleepiness Scale were employed to gage the extent of RLS's impact on sleep quality and daily functioning., Results: The prevalence of RLS amidst the MS cohort was determined to be 30.4%. An observable association was discerned between RLS presence and higher scores on the Expanded Disability Status Scale (p < 0.001), along with diminished sleep quality scores (p < 0.001) and elevated fatigue scores based on IRLSSG criteria (p < 0.001). Within the studied MS cases, 98.5 % exhibited the relapsing-remitting subtype. Further investigation demonstrated that patients treated with Fingolimod or Ocrevus presented normal IRLSSG scores, whereas those undergoing Rituximab treatment manifested an even distribution between normal and moderate scores. Correspondingly, patients receiving interferons showcased 72.2 % with normal scores and 27.8 % with mild scores. Notably, a statistically significant variance in IRLSSG scores was observed when contrasting Fingolimod and Aubagio treatments (P < 0.001)., Conclusion: The presence of RLS as a comorbidity in MS patients within the Saudi Arabian context emerges as a significant finding, exerting a discernible detrimental influence on both disability status and sleep quality. This study underscores the need for further investigations aimed at unraveling the intricate pathophysiological underpinnings, identification of risk factors, and exploration of therapeutic modalities for RLS in this population. Furthermore, additional research endeavors are warranted to elucidate the diverse impact of various disease-modifying therapies on clinical outcomes., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
37. Safety and efficacy of lithium in patients with amyotrophic lateral sclerosis: a systematic review and meta-analysis of randomized controlled trials.
- Author
-
Hamad AA, Attia AN, Al-Dardery NM, Mohamed SF, and Meshref M
- Subjects
- Humans, Lithium adverse effects, Valproic Acid adverse effects, Randomized Controlled Trials as Topic, Vital Capacity, Amyotrophic Lateral Sclerosis therapy
- Abstract
Objectives: This study provides a systematic review and meta-analysis of randomized controlled trials (RCTs) investigating the safety and efficacy of lithium in amyotrophic lateral sclerosis (ALS) patients., Methods: PubMed, Web of Science, Cochrane CENTRAL, Scopus, and Your Journals@Ovid were searched up to 9 December 2022. RCTs investigating lithium, either alone or with any supplement, in ALS patients were included. Meta-analysis was performed using RevMan and results are presented in forest plot., Results: Four RCTs with 469 patients met the inclusion criteria and were included in our study. Lithium doses varied among the included studies and one study used a combined therapy of lithium with valproate. Meta-analysis showed no difference between lithium and placebo regarding severe adverse events (odds ratio = 1.13, 95% confidence interval: 0.73 to 1.75, P = 0.58). No significant differences were observed with regard to survival rate between the two groups (hazard ratio = 0.95, 95% confidence interval: 0.65 to 1.37, P = 0.77). There were also no significant differences between the two groups with regard to average changes of revised amyotrophic lateral sclerosis functional rating scale (P = 0.35) and forced vital capacity percentage predicted (P = 0.73). Subgroup analysis showed no significant differences regarding all investigated outcomes either for lithium alone or lithium with valproate., Conclusion: Current evidence suggests a safety profile with no benefit of lithium for ALS. However, given the limited number of RCTs and the safety findings, we recommend further well-designed RCTs to investigate lithium and valproate in ALS patients., (© 2023. Fondazione Società Italiana di Neurologia.)
- Published
- 2023
- Full Text
- View/download PDF
38. Special considerations and pitfalls for intracerebral bleeding followed COVID-19 case treated by ECMO.
- Author
-
Amer WO, El Gharieb HA, Ahmed Z, Ibrahim H, Alanazi A, and Meshref M
- Abstract
COVID-19, or coronavirus infection, is an acute respiratory illness caused by the corona virus that can develop into a life-threatening form of ARDS. Extracorporeal membrane oxygenation (ECMO) is a highly effective treatment for life-threatening instances. One of the many complications associated with ECMO was bleeding. COVID patients are at risk for intracerebral bleeding due to several factors, including the drug's action on ACE2 receptors, leading to hypertension, as well as hypercoagulability, dysregulated immune response, DIC, and the use of anticoagulants., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2023 2020 International Hemorrhagic Stroke Association. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
39. Intracerebral hemorrhage associated COVID-19 patient with normal coagulation profile after ECMO treatment: A case report.
- Author
-
Osman Amer W, Awad El Gharieb H, Ibrahim H, Alanazi A, and Meshref M
- Abstract
Objective: Coronavirus disease 2019 (COVID-19) is a novel coronavirus-caused infectious acute respiratory disease that can progress to severe acute respiratory distress syndrome (ARDS). For severe cases, extracorporeal membrane oxygenation (ECMO) is an excellent treatment option. ECMO had a number of side effects, including bleeding. Intracerebral hemorrhage can occur in COVID patients due to a variety of mechanisms, including covid's effect on ACE-2 receptors and subsequent hypertension, coagulopathy, DIC, or medication, such as anticoagulant use., Case Presentation: We present a case of a 53-year-old male COVID-19 patient who developed multiple, massive, severe intracerebral hemorrhages (ICH) despite a normal coagulation profile after ECMO treatment., Conclusion: COVID-19 can progress to severe acute respiratory distress syndrome (ARDS), necessitating the use of extracorporeal membrane oxygenation (ECMO). Although ICH is not a common complication in patients with COVID-19 disease, it is unknown why this patient had a lower threshold of ICH despite having a normal coagulation profile., (© 2022 International Hemorrhagic Stroke Association. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
40. Gaming behavior disorder and its association with social phobia during COVID-19 pandemic: A cross-sectional study among the young Arabs.
- Author
-
Shaheen N, Shaheen A, Elmasry M, Abdelwahab OA, Mohamed A, Swed S, Rababah AA, Meshref M, Zaki A, and Shoib S
- Abstract
Background: Gaming addiction is a compulsive mental health condition that can have severe negative consequences on a person's life. As online gaming has increased during the COVID-19 pandemic, studies have shown a heightened risk of mental health issues. This study aims to assess the prevalence of severe phobia and addiction to online gaming among Arab adolescents and identify risk factors associated with these disorders., Methods: This cross-sectional study was conducted across 11 Arab nations. Participants were recruited using convenience sampling through an online survey distributed on social media platforms in 11 Arab countries. The survey included demographic questions, the Nine-item Internet Gaming Disorder Scale-Short Form (IGDS-SF9) to measure participants' online gaming addiction, the Social Phobia Scale (SPS), and questions assessing the impact of the COVID-19 pandemic on the prevalence of internet gaming addiction. The data were analyzed using SPSS win statistical package version 26., Results: Out of 2,458 participants, 2,237 were included in the sample due to non-response and missing data. The average age of the participants was 19.9 ± 4.8 years, and the majority were Egyptian and unmarried. 69% of the participants reported playing more than usual since the COVID-19 pandemic, as they were confined to their homes. Higher social phobia scores were associated with being single, male, and Egyptian. Participants from Egypt and those who felt that the pandemic significantly increased their gaming time had higher scores for online gaming addiction. Several major criteria, such as playing hours per day and beginning gaming at an early age, were associated with a higher level of online gaming addiction with social phobia., Conclusion: The study's findings suggest that there is a high prevalence of internet gaming addiction among Arab adolescents and young adults who play online games. The results also indicate a significant association between social phobia and several sociodemographic factors, which may inform future interventions and treatments for individuals with gaming addiction and social phobia., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Shaheen, Shaheen, Elmasry, Abdelwahab, Mohamed, Swed, Rababah, Meshref, Zaki and Shoib.)
- Published
- 2023
- Full Text
- View/download PDF
41. Clinical Characteristics, Course, and Outcomes of Vertebral Artery Dissections in the Postpartum Period; a Pooled Analysis of Published Case Reports.
- Author
-
Adel Diab R, Shaheen N, Mohamed A, Tarek Hefnawy M, Chofan Charo D, and Meshref M
- Abstract
Introduction: Vertebral artery dissection (VAD) is a rare, but life-threatening condition. Compared to the general population, pregnant and postpartum women are more likely to develop VAD. Spontaneous arterial dissections have an ambiguous pathophysiology and may be difficult to manage. This study aimed to pool and analyze the data of published cases in this regard., Methods: We conducted a literature search on February 24, 2022, using MeSH terms of interest in PubMed, Google Scholar, Ovid, Web of Science, and Scopus databases to find studies on VAD following childbirth., Results: A total of 28 studies were included in this review based on a database search. In the studies, 44 postpartum VAD (PPVAD) patients with a mean age of 34.26 ± 3.5 years were included. It took an average of 24.37± 13.7 days from delivery to dissection. 64% of the patients had developed unilateral dissection and 36% had developed bilateral dissection; 70% reported full recovery, and 9% did not achieve full recovery. The most common symptoms were headaches (89%), neck pain (64%), and hypertension (52%). The most common methods of diagnosis were magnetic resonance imaging (MRI) (64%) and computed tomography (CT) angiography (CTA) scan (66%). Only 8 (18%) cases reported the use of electrocardiography (ECG). The recorded outcomes of the patients with unilateral and bilateral postpartum VAD showed no statistical difference. Most of the included studies recommend early suspension and management for a better prognosis and prevention of complications., Conclusion: PPVAD is a severe medical condition but most cases were fully recovered after an early and proper antithrombotic plan for each case scenario., Competing Interests: The authors have no conflict of interest to declare
- Published
- 2023
- Full Text
- View/download PDF
42. COVID-19-Associated Cerebrovascular Events: A Case Series Study and a Literature Review of Possible Mechanisms.
- Author
-
Meshref M, Hewila IM, Khlidj Y, Korissi R, Shaheen N, Nashwan AJ, Ouerdane Y, Amro Y, Taher KM, and Ahmed MG
- Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects multiple body systems, including the nervous system. Cerebrovascular accidents can also occur. Patients with comorbid illnesses have severe manifestations and poor outcomes. Despite the proper mechanism of SARS-CoV-2 infection-associated stroke having not yet been settled, various possible mechanisms have been hypothesized. One possibility is that the virus causes endothelial dysfunction and immune-mediated injury. Another possibility is that the trans-neuronal spread of the virus affects brain tissue. In addition, hypercoagulability caused by SARS-CoV-2 infection could lead to a stroke. A virus-induced dysfunction of the renin-angiotensin system could also lead to a stroke. The immune response and vasculitis resulting from SARS-CoV-2 infection are also possible causes via a cytokine storm, immune dysfunction, and various inflammatory responses. SARS-CoV-2 infection may affect calcitonin gene-related peptides and cerebral blood flow and may lead to stroke. Finally, SARS-CoV-2 may cause hemorrhagic strokes via mechanisms stimulated by its interaction with angiotensin-converting enzyme 2 (ACE2), leading to arterial wall damage and blood pressure changes. In this article, we will present seven cases of stroke-associated SARS-CoV-2 infection., Competing Interests: The authors declare that they have no competing interests., (© 2023 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2023
- Full Text
- View/download PDF
43. An overview of third, fourth and sixth cranial nerve palsies in the setting of COVID-19: A case report and systematic review.
- Author
-
Meshref M, Shaheen N, Swed S, Ibrahim M, Mostafa MR, Algazar MO, Dobs M, Elsayed SI, Amro Y, Afsa A, and Morra ME
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Diplopia etiology, SARS-CoV-2, Abducens Nerve Diseases etiology, Abducens Nerve Diseases diagnosis, COVID-19 complications, Cranial Nerve Diseases diagnosis, Oculomotor Nerve Diseases etiology, Ophthalmoplegia diagnosis, Ophthalmoplegia etiology
- Abstract
Background: Covid-19 has serious sequelae that may be poorly understood, underreported, and, as a result, not diagnosed promptly, such as variations in clinical manifestations of hyperinflammation among people infected with SARS-CoV-2. ophthalmoplegia can be one of these manifestations., Methods: We are reporting a 55-year-old male patient with unilateral diplopia considering it as a case of multisystem inflammatory syndrome in adults. We also reviewed the literature systematically for the previously reported studies/cases with third, fourth and sixth cranial nerve palsies due to or after Covid-19., Results: The literature search yielded 17 studies reporting 29 patients. 71.4% of the patients were males with a mean age of 42.23 years. Ophthalmological symptoms took 9.7 days to appear after the respiratory involvement. All patients had diplopia as part of their visual symptoms. 41.4% of the patients had unilateral sixth nerve palsy, 24% had bilateral sixth nerve involvement, 17% had fourth nerve involvement, and 27.6% had third nerve involvement., Conclusion: Ophthalmoplegia is considered presenting symptom of Covid-19. Further research is needed to detect all neuro-ophthalmological manifestations of Covid-19., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
44. A rare case of Takotsubo syndrome with ventricular septal rupture: Case report.
- Author
-
Alsheikh H, Shaheen N, Saber W, Meshref M, Amro Y, Shaheen A, Ahmed MG, and Swed S
- Subjects
- Male, Humans, Adult, Chest Pain, Coronary Angiography, Ventricular Septal Rupture, Takotsubo Cardiomyopathy diagnosis, Takotsubo Cardiomyopathy etiology, Acute Coronary Syndrome
- Abstract
Introduction: Takotsubo cardiomyopathy (TCM) mimics acute coronary syndrome and is characterized by reversible left ventricular (LV) apical ballooning in the absence of angiographically substantial coronary artery stenosis., Patient Concerns: A 31-year-old man with acute dejection, physical stress, and psychological strain from the dread of losing his work arrived at the emergency department with chest pain, and discomfort that had lasted 3 hours., Diagnosis: Once the coronary angiography revealed normal epicardial coronaries, the case was retroactively diagnosed, and the levels of cardiac enzymes were increased., Interventions: The amount of necrotic tissue was so little that the surgeon could only verbally convey it. It is completely closed with the help of a Dacron sheet. The patient received surgical closure of the VSR a few days after having a surgical consultation., Outcomes: No postoperative echocardiogram was required, and the patient was sent home in great general condition., Conclusion: The presence of TCM with a ruptured LV wall was extremely rare because our patient had neither clinical risk indicators nor a family history of coronary artery disease. As a Takotsubo syndrome severe complication, we underline the significance of identifying, diagnosing, and treating it., Competing Interests: The authors have no funding and conflicts of interest to disclose., (Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
45. Could the New BA.2.75 Sub-Variant Cause the Emergence of a Global Epidemic of COVID-19? A Scoping Review.
- Author
-
Shaheen N, Mohamed A, Attalla A, Diab RA, Swed S, Nashwan AJ, Rababah AA, Hefnawy MT, Soliman Y, Abdelwahab OA, Desouki MT, Khaity A, Shaheen A, Ramadan A, and Meshref M
- Abstract
With over 58 million cases and 6 million deaths by August 2022, the Coronavirus disease 2019 (COVID-19), causing severe acute respiratory syndrome coronavirus 2 (SARs-CoV-2), has had an insurmountable impact on the world's population. This is one of the worst health crises since 1918's influenza pandemic. There are four subvariants of Omicron; BA.1, BA.1.1, BA.2 and BA.3. As a result of new mutations in its spike protein, most of which occur in its receptor binding site, the Omicron variant appears to be more transmissible and less resistant to vaccination and antibody response. Understanding Omicron's virology and mutations is essential to developing diagnostic and therapeutic methods. A thorough assessment of control measures, as well as timely adjustment of control measures, requires addressing such issues as re-infection risk, vaccine response, booster vaccine doses, and the increased rate of Omicron infections. This review article aims to look at the current information about the different types of SARs-CoV-2, focusing on the new subtype BA.2.75., Competing Interests: Dr Mahmoud Tarek Hefnawy reports non-financial support from Zagazig University Faculty of Medicine, during the conduct of the study. The remaining authors declare no competing interests., (© 2022 Shaheen et al.)
- Published
- 2022
- Full Text
- View/download PDF
46. Successful use of therapeutic anticoagulation therapy in two patients with moderate stroke from the second day of onset: A case report and literature review.
- Author
-
Meshref M, Shaheen N, Diab RA, Desouki MT, Amro Y, Khairat SM, Ali M, and Ahmed MG
- Abstract
Introduction and Importance: Hemorrhagic transformation of ischemic stroke is one of the most traumatic consequences of ischemic stroke. Therefore, deciding the optimal time for anticoagulant application and its effect on clinical outcome, recurrence and risk for hemorrhagic transformation are still in quarry. The European Heart Rhythm Association recommends the usage of anticoagulants after 3-4 days after a mild stroke, 6 days after moderate stroke and 12 days after a severe stroke., Case Presentation: In our case report, we present two patients who started full therapeutic anticoagulation of low molecular weight heparin from the first day after moderate ischemic stroke, warfarin was added later guided by INR and discharged on oral anticoagulants for associated AF. They improved clinically with improved motor function for both upper and lower limbs, sensation and gaze without any complication followed by serial CT., Clinical Discussion and Conclusion: As a result of this case report, clinical improvement has not been associated with hemorrhagic sequelae of anticoagulant administration on the first day. At this point, we recommend conducting a trial to study the effect of early application of anticoagulants from the first day on clinical outcome, recurrence, and hemorrhagic transfusion of stroke., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
47. Amoebic Hepato-Pericardial Fistula Complicating Amoebic Liver Abscess Treated With Pericardiotomy: A Case Report.
- Author
-
Alsheikh H, Shaheen N, Shaheen A, Raslan S, Meshref M, Amro Y, Swed S, and Nashwan AJ
- Abstract
Parasitic infections like amoebiasis are often asymptomatic in the tropics, but the invasive disease can cause an amoebic liver abscess. During pericardiocentesis, amoebiasis is more noticeable in left lobe abscesses with chocolate-like pus drainage. Here, we present an unusual amoebic liver abscess that erupted into the pericardial cavity via a diaphragmatic fistula. An emergency pericardiotomy was performed to relieve cardiac tamponade, and the liver abscess was evacuated through a diaphragmatic rent identified during the surgery. This illustrates the catastrophic complications of an amoebic liver abscess., Competing Interests: The authors have declared that no competing interests exist., (Copyright © 2022, Alsheikh et al.)
- Published
- 2022
- Full Text
- View/download PDF
48. Is there a need to be worried about the new monkeypox virus outbreak? A brief review on the monkeypox outbreak.
- Author
-
Shaheen N, Diab RA, Meshref M, Shaheen A, Ramadan A, and Shoib S
- Abstract
The Monkeypox virus (MPXV) is a double-stranded DNA virus related to the orthopoxvirus genus in the family of poxviridae. MPXV is endemic in central and Western African countries. There have been several outbreaks of MPXV in non-endemic countries since it was discovered in 1958 in lab monkeys. The current spread of MPXV is different from previous outbreaks, raising concerns about its potential to cause pandemics around the world. In order to reduce the spread of the disease, several countries imposed different preventive measures. The MPXV virus is believed to be transmitted either through wild animals, such as rodents or through infected individuals. Every year, Africa experiences a few thousand cases, mostly in the west and central regions. The number of cases outside Africa has previously been limited to a handful associated with travel to Africa or with the importation of infected animals. In this narrative review, we will discuss the clinical diagnosis, transmission, distribution, treatment, and prevention of the recent monkeypox outbreak around the world., Competing Interests: All authors have no conflict of interest to disclose., (© 2022 The Authors.)
- Published
- 2022
- Full Text
- View/download PDF
49. Central positional vertigo as first initial multiple sclerosis symptom: A case report with systematic review.
- Author
-
Meshref M, Shaheen A, Elmatboly AM, Hamdallah A, Abdella WS, Amro Y, Khairat SM, and Swed S
- Abstract
Multiple sclerosis is a disease that affects the central nervous system, resulting in various symptoms such as vision, physical activity, and stability. Central positional vertigo as initial multiple sclerosis symptoms are a rare case. It increases the attention of doctors to follow accurate measurements to diagnose multi sclerosis regarding the initial symptoms., (© 2022 Aleppo University. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
50. Subdural empyema due to mixed infections successfully treated medically: A case report with review literature.
- Author
-
Meshref M, Nourelden AZ, Elshanbary AA, AbdelQadir YH, Zaazouee MS, Ragab KM, Ahmed EMS, and Swed S
- Abstract
Subdural empyema is a rare intracranial infection with an accumulation of purulent material between the dura and arachnoid matter. We report a case of 17 years old presented with an altered conscious level. CSF analysis showed increased WBCs. His situation has improved after treating by acyclovir, ceftriaxone, vancomycin, and dexamethasone., Competing Interests: There is no conflict of interest., (© 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.